Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report

No authors: listed: T he World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Histopathology. Pathol Int. 50:696–702. 2000. View Article : Google Scholar : PubMed/NCBI

Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Suefuji N and Kikuchi M: Distribution of malignant lymphoma in Japan, Analysis of 2260 cases, 2001-2006. Pathol Int. 58:174–182. 2008. View Article : Google Scholar : PubMed/NCBI

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T and Uike N: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 32:1157–1163. 2014. View Article : Google Scholar : PubMed/NCBI

Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematolopoietic and Lymphoid Tissues (4th). Lyon: IARC. 2008.

Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K and Yoshie O: Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 11:81–88. 1999. View Article : Google Scholar : PubMed/NCBI

Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K and Ueda R: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64:2127–2133. 2004. View Article : Google Scholar : PubMed/NCBI

Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, et al: Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 16:1520–1531. 2010. View Article : Google Scholar : PubMed/NCBI

Ohshima K, Karube K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, Suzumiya J and Kikuchii M: Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression, Analysis of prognosis. Int J Oncol. 25:605–613. 2004.PubMed/NCBI

Nakagawa M, Nakagawa-Oshiro A, Karnan S, Tagawa H, Utsunomiya A, Nakamura S, Takeuchi I, Ohshima K and Seto M: Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res. 15:30–38. 2009. View Article : Google Scholar : PubMed/NCBI

Ishida T and Ueda R: Immunopathogenesis of lymphoma: Focus on CCR4. Cancer Sci. 102:44–50. 2011. View Article : Google Scholar : PubMed/NCBI

Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, Takeuchi G, Eimoto T, Nakamura S and Ueda R: CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 10:5494–5500. 2004. View Article : Google Scholar : PubMed/NCBI

Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, et al: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 28:1591–1598. 2010. View Article : Google Scholar : PubMed/NCBI

Duvic M, Pinter-Brown L, Foss FM, Sokol L, Jorgensen JL, et al: Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 125:1883–1889. 2015. View Article : Google Scholar : PubMed/NCBI